Sight Sciences Appoints Matt Link as Chief Commercial Officer
11 Setembro 2023 - 5:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative technology intended to transform care
and improve patients' lives, today announced the appointment of
Matthew Link as its Chief Commercial Officer, effective September
11, 2023.
“We are very excited to have Matt join Sight
Sciences as we scale our Surgical Glaucoma and Dry Eye businesses.
Matt is a highly talented medtech business leader with a track
record of success in transforming treatment paradigms with
disruptive new technology, and predictably scaling in a public
high-growth medtech setting. We believe his market development
experience with procedurally focused, less invasive solutions
utilizing disruptive technology that transformed spine surgery
positions him well to accelerate the procedural transformation of
glaucoma and dry eye disease treatment with our interventional
OMNI® Surgical System and TearCare® System technologies. Matt
joined NuVasive at a time when it had similar revenue levels as
Sight Sciences does today and helped scale NuVasive’s business over
the ensuing years to profitability with over $1 billion in
revenue,” said Paul Badawi, Founder and Chief Executive Officer of
Sight Sciences. “We are confident Matt’s addition will further
enhance the capabilities of our strong executive team. We are
looking forward to him leading the commercial organization,
advancing our strategic plans, and ensuring we have the appropriate
infrastructure to support significant and profitable growth over
the coming years.”
Mr. Link added, “I am delighted to be joining
Sight Sciences at this critical juncture as the glaucoma and dry
eye categories are undergoing significant transformation. Sight
Sciences is a leader in eyecare technology innovation with a
portfolio and pipeline of products that are elevating the standard
of care. I am ready to leverage my strong commercial strategy and
development background in high-growth medtech to help Sight
Sciences achieve its fullest potential. I look forward to working
with Paul and the Sight Sciences team to improve the lives of our
patients and help the Company achieve its growth and profitability
objectives.”
Mr. Link has more than 20 years of experience
building teams and leading innovation in the healthcare and medical
technology industries, most recently serving as Managing Partner at
Orion Healthcare Advisors, LLC, a consulting services provider.
Before Orion, Mr. Link spent nearly 15 years in regional and
executive leadership positions at NuVasive, Inc., a global leader
in surgical implants and enabling technology for spine surgery and
orthopedics, where he designed and executed strategies that
supported the company’s revenue growth from less than $100 million
to over $1 billion. Mr. Link joined NuVasive as an Area
Business Manager and rose to the level of President where his
responsibilities included oversight of global business units in
spine, neurophysiology and orthopedics. Prior to NuVasive, Mr. Link
held commercial leadership roles at Depuy Orthopedics and Depuy
Spine. He currently serves as a member of the board of
directors of Springbok Analytics, Fibrobiologics and
DinamicOR. Additionally, he serves on the board of directors
of the Coulter Translational Research Endowment at the University
of Virginia. Mr. Link received a BSEd in Physical Education and
Sports Medicine from the University of Virginia.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative solutions to transform care and improve
patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional, outdated approaches. The Company’s OMNI®
Surgical System is an implant-free glaucoma surgery technology that
reduces intraocular pressure in adult patients with primary
open-angle glaucoma (POAG), the world’s leading cause of
irreversible blindness. The Company’s TearCare® System technology
is 510(k) cleared for the application of localized heat therapy in
adult patients with evaporative dry eye disease due to meibomian
gland dysfunction (MGD) when used in conjunction with manual
expression of the meibomian glands, enabling office-based clearance
of gland obstructions by physicians to address the leading cause of
dry eye disease. The Company’s SION™ Surgical Instrument is a
manually operated device used in ophthalmic surgical procedures to
excise trabecular meshwork.
For more information,
visit www.sightsciences.com.
OMNI and TearCare are registered trademarks of Sight
Sciences.SION is a trademark of Sight Sciences.© 2023 Sight
Sciences. All rights reserved.
Forward-Looking StatementsThis
press release, together with other statements and information
publicly disseminated by the Company, contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which statements are
subject to considerable risks and uncertainties. The Company
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 and includes this
statement for purposes of complying with these safe harbor
provisions. Any statements made in this press release that are not
statements of historical fact, including statements about our
beliefs and expectations, are forward-looking statements and should
be evaluated as such. Forward-looking statements include all
statements other than statements of historical fact, including
statements concerning the perceived benefits of the Company’s
announced Chief Commercial Officer appointment, and should be
evaluated as such. These statements often include words such as
“anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,”
“estimates,” “targets,” “projects,” “should,” “could,” “would,”
“may,” “will,” “forecast” and other similar expressions. We base
these forward-looking statements on our current expectations, plans
and assumptions that we have made in light of our experience in the
industry, as well as our perceptions of historical trends, current
conditions, expected future developments and other factors we
believe are appropriate under the circumstances at such time.
Although management believes these forward-looking statements are
based upon reasonable assumptions at the time they are made,
management cannot guarantee their accuracy or completeness.
Forward-looking statements are subject to and involve risks,
uncertainties and assumptions that may cause the Company’s actual
results, performance or achievements to be materially different
from any future results, performance, or achievements predicted,
assumed or implied by such forward-looking statements. Some of the
risks and uncertainties that may cause actual results to materially
differ from those expressed or implied by these forward-looking
statements are discussed under the caption “Risk Factors” in the
Company’s filings with the SEC, as may be updated from time to time
in subsequent filings. These cautionary statements should not be
construed by you to be exhaustive and are made only as of the date
of this press release. Sight Sciences undertakes no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by applicable law.
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024